25 October 2016 - CADTH has recommended Gilead's new combination product for patients with chronic hepatitis C virus infection.

The CADTH Canadian Drug Expert Committee has recommended that sofosbuvir/velpatasvir be reimbursed for the treatment of chronic hepatitis C (CHC) infection, if the following criterion and condition are met:

• Treatment should be initiated by physicians with experience in the management of patients with CHC.
  
• Reduced price.
  

Read CADTH outcome for Epclusa